Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...

Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults with moderate to severe active thyroid eye disease (T ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

In the new subcutaneous drug delivery landscape, the growing trend towards patient-friendly, at-home administration is ...

The FDA granted Priority Review to the supplemental BLA (sBLA) for efgartigimod alfa-fcab for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia ...

In December 2025, Fennec announced that City of Hope, a U.S. cancer research and treatment organization, is evaluating PEDMARK ® for the prevention of cisplatin-induced ototoxicity (CIO) in adult men ...

A half-million-dollar corporate retreat to Honduras turned into a week-long disaster involving illness, wild animals, armed ...

In the latest tranche of published warning letters, the US Food and Drug Administration (FDA) has continued to go after ...

Artemis II live: ‘Spirits high’ among Nasa crew as spacecraft returns to Earth after record-breaking mission - A 15-second ...

Medetomidine is the direct successor to xylazine. It's not associated with soft-tissue infections, but has distinct side ...